358 related articles for article (PubMed ID: 25655085)
1. Point-of-care platelet function testing predicts bleeding in patients exposed to clopidogrel undergoing coronary artery bypass grafting: Verify pre-op TIMI 45--a pilot study.
Reed GW; Kumar A; Guo J; Aranki S; Shekar P; Agnihotri A; Maree AO; McLean DS; Rosenfield K; Cannon CP
Clin Cardiol; 2015 Feb; 38(2):92-8. PubMed ID: 25655085
[TBL] [Abstract][Full Text] [Related]
2. Platelet activity measured by a rapid turnaround assay identifies coronary artery bypass grafting patients at increased risk for bleeding and transfusion complications after clopidogrel administration.
Rosengart TK; Romeiser JL; White LJ; Fratello A; Fallon E; Senzel L; Shroyer AL
J Thorac Cardiovasc Surg; 2013 Nov; 146(5):1259-1266, 1266.e1; discussion 1266. PubMed ID: 23953984
[TBL] [Abstract][Full Text] [Related]
3. Is There an Ideal Level of Platelet P2Y12-Receptor Inhibition in Patients Undergoing Percutaneous Coronary Intervention?: "Window" Analysis From the ADAPT-DES Study (Assessment of Dual AntiPlatelet Therapy With Drug-Eluting Stents).
Kirtane AJ; Parikh PB; Stuckey TD; Xu K; Witzenbichler B; Weisz G; Rinaldi MJ; Neumann FJ; Metzger DC; Henry TD; Cox DA; Duffy PL; Brodie BR; Mazzaferri EL; Parvataneni R; Maehara A; Généreux P; Mehran R; Stone GW
JACC Cardiovasc Interv; 2015 Dec; 8(15):1978-1987. PubMed ID: 26738669
[TBL] [Abstract][Full Text] [Related]
4. The role of platelet reactivity assessment in dual antiplatelet prophylaxis after transcatheter aortic valve implantation.
Czerwińska-Jelonkiewicz K; Witkowski A; Dąbrowski M; Piotrowski W; Hryniewiecki T; Stępińska J
Arch Cardiovasc Dis; 2018 Apr; 111(4):233-245. PubMed ID: 29126843
[TBL] [Abstract][Full Text] [Related]
5. Platelet Function Testing and Prediction of Bleeding in Patients Exposed to Clopidogrel Undergoing Coronary Artery Surgery.
Petricevic M; Biocina B; Milicic D; Rotim C; Boban M
Clin Cardiol; 2015 Jul; 38(7):443-4. PubMed ID: 25998754
[No Abstract] [Full Text] [Related]
6. Usefulness of platelet response to clopidogrel by point-of-care testing to predict bleeding outcomes in patients undergoing percutaneous coronary intervention (from the Antiplatelet Therapy for Reduction of Myocardial Damage During Angioplasty-Bleeding Study).
Patti G; Pasceri V; Vizzi V; Ricottini E; Di Sciascio G
Am J Cardiol; 2011 Apr; 107(7):995-1000. PubMed ID: 21256470
[TBL] [Abstract][Full Text] [Related]
7. A therapeutic window for platelet reactivity for patients undergoing elective percutaneous coronary intervention: results of the ARMYDA-PROVE (Antiplatelet therapy for Reduction of MYocardial Damage during Angioplasty-Platelet Reactivity for Outcome Validation Effort) study.
Mangiacapra F; Patti G; Barbato E; Peace AJ; Ricottini E; Vizzi V; Gatto L; D'Ambrosio A; De Bruyne B; Wijns W; Di Sciascio G
JACC Cardiovasc Interv; 2012 Mar; 5(3):281-9. PubMed ID: 22440493
[TBL] [Abstract][Full Text] [Related]
8. The STIB score: a simple clinical test to predict clopidogrel resistance.
Legrand D; Barbato E; Chenu P; Magne J; Vrolix M; Wijns W; Legrand V;
Acta Cardiol; 2015 Oct; 70(5):516-21. PubMed ID: 26567810
[TBL] [Abstract][Full Text] [Related]
9. High-dose atorvastatin on the pharmacodynamic effects of double-dose clopidogrel in patients undergoing percutaneous coronary interventions: The ACHIDO (Atorvastatin and Clopidogrel HIgh DOse in stable patients with residual high platelet activity) study.
Leoncini M; Toso A; Maioli M; Angiolillo DJ; Giusti B; Marcucci R; Abbate R; Bellandi F
JACC Cardiovasc Interv; 2013 Feb; 6(2):169-79. PubMed ID: 23428009
[TBL] [Abstract][Full Text] [Related]
10. Switching acute coronary syndrome patients from prasugrel to clopidogrel.
Kerneis M; Silvain J; Abtan J; Cayla G; O'Connor SA; Barthélémy O; Vignalou JB; Beygui F; Brugier D; Martin R; Collet JP; Montalescot G
JACC Cardiovasc Interv; 2013 Feb; 6(2):158-65. PubMed ID: 23428007
[TBL] [Abstract][Full Text] [Related]
11. A randomised study for optimising crossover from ticagrelor to clopidogrel in patients with acute coronary syndrome. The CAPITAL OPTI-CROSS Study.
Pourdjabbar A; Hibbert B; Chong AY; Le May MR; Labinaz M; Simard T; Ramirez FD; Lugomirski P; Maze R; Froeschl M; Glover C; Dick A; Marquis JF; Bernick J; Wells G; So DY;
Thromb Haemost; 2017 Jan; 117(2):303-310. PubMed ID: 27761582
[TBL] [Abstract][Full Text] [Related]
12. Multi-institutional patterns of clopidogrel response among patients undergoing transcarotid artery revascularization.
Rokosh RS; Rockman C; Garg K; Wang SK; Motaganahalli RL; Schroeder AC; Sobraske PJ; Stoner MC; Tarbunou YA; Marmor RA; Malas MB; Maldonado TS
Vascular; 2024 Jun; 32(3):558-564. PubMed ID: 36428145
[TBL] [Abstract][Full Text] [Related]
13. Precatheterization Use of P2Y
Badri M; Abdelbaky A; Li S; Chiswell K; Wang TY
J Am Heart Assoc; 2017 Sep; 6(9):. PubMed ID: 28939715
[TBL] [Abstract][Full Text] [Related]
14. Influence of smoking on the antiplatelet effect of clopidogrel differs according to clopidogrel dose: Insights from the GRAVITAS trial.
Reed GW; Cannon CP; Waalen J; Teirstein PS; Tanguay JF; Berger PB; Angiolillo DJ; Price MJ
Catheter Cardiovasc Interv; 2017 Feb; 89(2):190-198. PubMed ID: 26909669
[TBL] [Abstract][Full Text] [Related]
15. The effect of acenocoumarol on the antiplatelet effect of clopidogrel.
Dewilde WJ; Janssen PW; Bergmeijer TO; Kelder JC; Hackeng CM; ten Berg JM
Thromb Haemost; 2015 Oct; 114(4):708-16. PubMed ID: 26177793
[TBL] [Abstract][Full Text] [Related]
16. Impact of platelet inhibition level on subsequent no-reflow in patients undergoing primary percutaneous coronary intervention for ST-segment elevation myocardial infarction.
Aitmokhtar O; Paganelli F; Benamara S; Azaza A; Bonello L; Hamza O; Seddiki S; Benathmane T; Saidane M; Bouzid A; Kara M; Sik A; Azzouz A; Harbi F; Monsuez JJ; Benkhedda S
Arch Cardiovasc Dis; 2017 Nov; 110(11):626-633. PubMed ID: 28583820
[TBL] [Abstract][Full Text] [Related]
17. A comparative cohort study on personalised antiplatelet therapy in PCI-treated patients with high on-clopidogrel platelet reactivity. Results of the ISAR-HPR registry.
Mayer K; Schulz S; Bernlochner I; Morath T; Braun S; Hausleiter J; Massberg S; Schunkert H; Laugwitz KL; Kastrati A; Sibbing D
Thromb Haemost; 2014 Aug; 112(2):342-51. PubMed ID: 24718389
[TBL] [Abstract][Full Text] [Related]
18. Cigarette Smoking Does Not Enhance Clopidogrel Responsiveness After Adjusting VerifyNow P2Y12 Reaction Unit for the Influence of Hemoglobin Level.
Kim YG; Suh JW; Kang SH; Park JJ; Yoon CH; Cho YS; Youn TJ; Chae IH; Choi DJ; Kim HS
JACC Cardiovasc Interv; 2016 Aug; 9(16):1680-90. PubMed ID: 27539687
[TBL] [Abstract][Full Text] [Related]
19. Platelet function testing to predict hyporesponsiveness to clopidogrel in patients with chest pain seen in the emergency department.
Sharma RK; Erickson SW; Sharma R; Voelker DJ; Reddy HK; Dod H; Marsh JD
Vasc Health Risk Manag; 2013; 9():187-93. PubMed ID: 23662064
[TBL] [Abstract][Full Text] [Related]
20. Optimal timing of clopidogrel discontinuation in Japanese patients: platelet aggregation test using the VerifyNow® system.
Takiuchi H; Tanemoto K
Gen Thorac Cardiovasc Surg; 2015 Nov; 63(11):601-6. PubMed ID: 26298730
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
